Zevra Therapeutics (ZVRA) announced, on Rare Disease Day, the launch of a new disease state awareness campaign, ‘Learn NPC, Read Between the ...

Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won ...

Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...

Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Jones brings a broad background beyond the pharma space, having led or worked in HR at Sangamo Therapeutics and Novartis Diagnostics, as well as LendingClub and Gap, Inc. More from the Boards.